NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders, announces that the Centers for Medicare & Medicaid Services (“CMS”) is establishing two new Level II Healthcare Common Procedure Coding System (“HCPCS”) codes for the Monarch eTNS System®
| LOS ANGELES, Jan. 22, 2021 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders, announces that the Centers for Medicare & Medicaid Services (“CMS”) is establishing two new Level II Healthcare Common Procedure Coding System (“HCPCS”) codes for the Monarch eTNS System®, effective April 1, 2021, as part of the final coding decisions of its Second Biannual, 2020 Coding Cycle for Non-Drug and Non-Biological Items and Services. The new codes are K1016 (Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve) and K1017 (Monthly supplies for use of device coded at K1016). Securing these codes is an important milestone in enabling payer coverage and payment decisions.
Hogan Lovells US LLP represented and assisted NeuroSigma in the review by CMS of NeuroSigma’s application. “We are extremely pleased by the decision of CMS to establish unique codes and want to thank CMS staff for their efforts during the review process to bring it to a timely and successful completion. We would also like to thank Dr. James McGough, lead investigator of the pivotal eTNS ADHD trial conducted at UCLA, for his assistance during the CMS review process,” said Leon Ekchian, Ph.D., President & CEO of NeuroSigma. “NeuroSigma’s Monarch eTNS System was the first non-drug treatment for pediatric ADHD cleared by the FDA. Starting April 1st of this year, payers will be able to use these unique new HCPCS codes to establish coverage policies and payment decisions,” said Ian Cook, M.D., Chief Medical Officer of NeuroSigma. “CMS’ decision to establish unique Level II HCPCS codes for both the Monarch eTNS System and refills of the disposable single use patches should facilitate access to this important new treatment modality by children with ADHD,” said Colin Kealey, M.D., NeuroSigma’s Vice President of Medical Affairs. “With the benefit of these new HCPCS codes, we look forward to building a commercial organization in the U.S. to offer children, parents, and physicians a compelling non-drug alternative to current medication treatment options for ADHD,” added Kealey. Background – eTNS In the European Union, the Monarch eTNS System is approved as adjunctive therapy for drug resistant epilepsy and major depressive disorder, as well as monotherapy for ADHD, all in patients 7 years and older. The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain, bilaterally and at high frequency. The trigeminal nerve projects directly or indirectly to specific areas of the brain, such as the locus coeruleus, nucleus tractus solitarius, thalamus, and the cerebral cortex, which are involved in attention-deficit hyperactivity disorder (ADHD) and other disorders. Trigeminal Nerve Stimulation (TNS) is mild electrical stimulation of branches of the trigeminal nerve, including those located near the surface of the forehead. Functional neuroimaging data suggests the mechanism of action of TNS is related to its ability to modulate activity in targeted brain regions. eTNS is the external embodiment of TNS and is patent protected in the United States and other major potential markets. eTNS, Monarch, and Monarch eTNS are trademarks of NeuroSigma, Inc. For more information on eTNS, please visit the Monarch eTNS website. About NeuroSigma, Inc. Forward-Looking Safe Harbor Statement Media Contact
SOURCE NeuroSigma, Inc. |
View original content to download multimedia:
